NASDAQ | ETF
The fund invests at least 80% of its total assets in the securities of the underlying index.
The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| MRNA | Moderna Inc | Healthcare | Biotechnology | 6.83% |
| ARWR | Arrowhead Pharmaceuticals Inc | Healthcare | Biotechnology | 5.83% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 5.66% |
| GH | Guardant Health Inc | Healthcare | Diagnostics & Research | 5.58% |
| PRAX | Praxis Precision Medicines Inc | Healthcare | Biotechnology | 5.28% |
| NTRA | Natera Inc | Healthcare | Diagnostics & Research | 4.40% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 4.02% |
| BNTX | BioNTech SE | Healthcare | Biotechnology | 4.01% |
| BMRN | Biomarin Pharmaceutical Inc | Healthcare | Biotechnology | 3.85% |
| QIA | QIAGEN NV | Healthcare | Diagnostics & Research | 3.84% |
| TECH | Bio-Techne Corp | Healthcare | Biotechnology | 3.83% |
| RNA | Avidity Biosciences Inc | Healthcare | Biotechnology | 3.66% |
| QGEN | Qiagen NV | Healthcare | Diagnostics & Research | 3.66% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 3.07% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 2.64% |
| VCYT | Veracyte Inc | Healthcare | Diagnostics & Research | 2.57% |
| BEAM | Beam Therapeutics Inc | Healthcare | Biotechnology | 2.33% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 2.29% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.25% |
| WGS | GeneDx Holdings Corp. | Healthcare | Diagnostics & Research | 2.19% |